

Development of mPGES-1 targeted anti-inflammatory mechanism-based arthritis and pain treatment

Kukje pharma



IMMUNOLOGY	Preclinical
Product Type	Small molecule
Indication	Inflammatory and pain-related disorders(Osteoarthritis etc)
Target	mPGES-1
MoA(Mechanism of Action)	KJN-02-142 selectively inhibits mPGES-1, an enzyme that converts PGH ₂ to PGE ₂ , suppressing PGE ₂ production. Through this selective action, it reduces inflammation and pain without inhibiting other prostanoids, resulting in fewer gastrointestinal and cardiovascular side effects associated with COX inhibitors.
Competitiveness	Best in Class KJN-02-142 will have a strong competitive advantages as a next-generation anti-inflammatory agent, offering high selectivity and improved safety compared with COX inhibitors
Development Stage	Preclinical
Route of Administration	po

Any unauthorized distribution or reproduction of this material is strictly prohibited.